Efficacy of two novel antifungal lipopeptides, AF and AF of bacillomycin D family in murine models of invasive candidiasis, cryptococcosis, and aspergillosis.

Invasive fungal diseases are an important public health concern due to an increase in the at-risk population and high mortality associated with these infections. Managing invasive fungal infections poses a significant challenge given the limited antifungal options and the emergence of resistance in key fungal pathogens. Through a comprehensive approach, we evaluated the in vitro antifungal activity and the in vivo efficacy of two novel lipopeptides, AF and AF in murine models of disseminated candidiasis, cryptococcosis, and aspergillosis.

Two promising natural lipopeptides from effectively induced membrane permeabilization in .

is an important opportunistic human pathogen well known to develop resistance to antifungal drugs. Due to their numerous desirable qualities, antimicrobial lipopeptides have gained significant attention as promising candidates for antifungal drugs. In the present study, two bioactive lipopeptides (AF and AF m/z 1071.

Two promising -derived antifungal lipopeptide leads AF and AF and their combined effect with fluconazole on the biofilms.

species are endowed with the ability to produce biofilms, which is one of the causes of pathogenicity, as biofilms protect yeasts from antifungal drugs. () is one of the most prevalent pathogenic yeasts in humans and a biofilm producer. The study was aimed at evaluating the combined effects of two highly promising antifungal biomolecules (AF and AF) lipopeptide in nature, chromatographically purified to homogeneity from () and the standard antifungal fluconazole (at different concentrations) to demonstrate biofilm formation inhibition.

Functional Characterization of a -Derived Novel Broad-Spectrum Antifungal Lipopeptide Variant against Candida tropicalis and Candida auris and Unravelling Its Mode of Action.

Limited treatment options, recalcitrance, and resistance to existing therapeutics encourage the discovery of novel antifungal leads for alternative therapeutics. Antifungal lipopeptides have emerged as potential candidates for developing new and alternative antifungal therapies. In our previous studies, we isolated and identified the lipopeptide variant AF and purified it to homogeneity via chromatography from the cell-free supernatant of Bacillus subtilis.